MX2022005815A - Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. - Google Patents

Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.

Info

Publication number
MX2022005815A
MX2022005815A MX2022005815A MX2022005815A MX2022005815A MX 2022005815 A MX2022005815 A MX 2022005815A MX 2022005815 A MX2022005815 A MX 2022005815A MX 2022005815 A MX2022005815 A MX 2022005815A MX 2022005815 A MX2022005815 A MX 2022005815A
Authority
MX
Mexico
Prior art keywords
lymphocytes
genetically modified
therapy
target
hematopoietic cells
Prior art date
Application number
MX2022005815A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Alexander Terrett
Mary- Lee DEQUÉANT
Matthias Will
Original Assignee
Crispr Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag filed Critical Crispr Therapeutics Ag
Publication of MX2022005815A publication Critical patent/MX2022005815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2022005815A 2019-11-13 2020-11-13 Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. MX2022005815A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934945P 2019-11-13 2019-11-13
US202063034510P 2020-06-04 2020-06-04
PCT/IB2020/060718 WO2021095009A1 (en) 2019-11-13 2020-11-13 Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70

Publications (1)

Publication Number Publication Date
MX2022005815A true MX2022005815A (es) 2022-08-10

Family

ID=73554470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005815A MX2022005815A (es) 2019-11-13 2020-11-13 Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.

Country Status (11)

Country Link
US (1) US20220387571A1 (enExample)
EP (1) EP4058051A1 (enExample)
JP (1) JP2023501590A (enExample)
KR (1) KR20220100912A (enExample)
CN (1) CN114845730A (enExample)
AU (1) AU2020384951A1 (enExample)
BR (1) BR112022009290A2 (enExample)
CA (1) CA3158090A1 (enExample)
IL (1) IL292467A (enExample)
MX (1) MX2022005815A (enExample)
WO (1) WO2021095009A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20220387488A1 (en) * 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20230128917A1 (en) * 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
CN117173092B (zh) * 2023-06-28 2024-04-09 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种基于图像处理的鼻咽癌放疗方法及系统
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466291B2 (en) * 2016-07-06 2022-10-11 Cellectis Sequential gene editing in primary immune cells
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
MX2020008184A (es) * 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer

Also Published As

Publication number Publication date
CA3158090A1 (en) 2021-05-20
BR112022009290A2 (pt) 2022-08-09
KR20220100912A (ko) 2022-07-18
EP4058051A1 (en) 2022-09-21
US20220387571A1 (en) 2022-12-08
IL292467A (en) 2022-06-01
WO2021095009A1 (en) 2021-05-20
CN114845730A (zh) 2022-08-02
AU2020384951A1 (en) 2022-05-19
AU2020384951A9 (en) 2023-06-29
JP2023501590A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CR20210042A (es) RECEPTORES DE ANTÍGENOS QUIMÉRICOS DIRIGIDOS A BCMA Y MÉTODOS DE USO DE ESTOS (Divisional 2019-0050)
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AR125851A1 (es) Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
MX2017015046A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
CU20180033A7 (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
MX2021013960A (es) Receptores de antígeno quimérico (car) de mesotelina y sus usos.
BR112022009204A2 (pt) Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
UY35964A (es) Anticuerpos humanos para pd?1
PE20191847A1 (es) Receptores de antigenos quimericos que se dirigen a flt3
MX2016010345A (es) Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas.
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
CL2018003349A1 (es) Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b.
MX2023002373A (es) Receptores de antígenos quiméricos bcma.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso